Names that match “USA Inc”
1,609 documents found
nett I, 274 F.Supp.2d at 104. Proximate
document IMAGES-004-HOUSE_OVERSIGHT_017891.txt House Oversight Committee — Epstein Estate Records (Nov 2025)
…his
conduct, but only to those with respect to
whom his acts were a substantial factor in
the sequence of responsible causation, and
whose injury was reasonably foreseeable
or anticipated as a natural consequence.”).
In light of al Qaeda’s public acknowledg-
ments of its war agai...
1533, 1537 (S.D.N.Y.1983) (holding corre
document IMAGES-004-HOUSE_OVERSIGHT_017885.txt House Oversight Committee — Epstein Estate Records (Nov 2025)
820
1533, 1537 (S.D.N.Y.1983) (holding corre-
spondent banking relationships insufficient
to create general personal jurisdiction).
NCB offers its customers the opportunity
to open accounts directly with United
States-based securities broker-dealers, but
NCB does not act as a br...
Bellingham, Washington
document IMAGES-008-HOUSE_OVERSIGHT_024794.txt House Oversight Committee — Epstein Estate Records (Nov 2025)
Or
>
A
“Bw
Plan
fon on
RO RUBICON
. . ORGANICS
Rubicon Organics
Bellingham, Washington
www.rubiconorganics.com
Rubicon Organics is a licensed cannabis culti-
vator specializing in the growing, processing,
packaging and marketing of cannabis. The com-
pany is developing greenho...
Paul J. Set Theory and the Continuum Hypothesis. Dover Publications Inc
document Cohen House Oversight Committee — Epstein Estate Records (Nov 2025)
Paul J. Set Theory and the Continuum Hypothesis. Dover Publications Inc.
and/or was involved in Novamente LLC and Webmind Inc
document involved with the OpenCog project House Oversight Committee — Epstein Estate Records (Nov 2025)
and/or was involved in Novamente LLC and Webmind Inc.
Inc. Therapeutics 7.7 19.4 - 19.4 2.51 2.51 581.9%
document Acadia Phamaceuticals House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 7.7 19.4 - 19.4 2.51 2.51 581.9%
Inc. Therapeutics 2013 10.4 11.1 - 11.1 1.06 1.06 13.1%
document Ambit Biosciences House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2013 10.4 11.1 - 11.1 1.06 1.06 13.1%
Inc. Convergence 2011 88: 125 1.6 14.1 - 3.68 105.6%
document Audax Health Solutions House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Convergence 2011 88: 125 1.6 14.1 - 3.68 105.6%
Inc. Therapeutics 2011 20.6 27.0 44.9 71.9 3.07 3.50 57.7%
document Chimerix House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2011 20.6 27.0 44.9 71.9 3.07 3.50 57.7%
Inc. Therapeutics 2013 3.4 6.8 - 6.8 2.03 2.03 1583.0%
document Epizyme House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2013 3.4 6.8 - 6.8 2.03 2.03 1583.0%
Inc. Diagnostics & Infrastructure 2008 10.7 - - - - - NM
document Glumetrics House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Diagnostics & Infrastructure 2008 10.7 - - - - - NM
Inc. Therapeutics 2012 10.5 34.1 - 34.1 3.24 3.24 323.6%
document Intercept Pharmaceuticals House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2012 10.5 34.1 - 34.1 3.24 3.24 323.6%
Inc. Therapeutics 2011 2.4 02 - 0.2 0.07 0.07 -91.6%
document Kalidex Pharmaceuticals House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2011 2.4 02 - 0.2 0.07 0.07 -91.6%
Inc. Therapeutics 2012 9.0 10.2 35.8 46.0 2.94 5.12 423.2%
document MEI Pharma House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2012 9.0 10.2 35.8 46.0 2.94 5.12 423.2%
Inc. Therapeutics 2009 11.0 - - - - - NM
document Presidio Pharmaceuticals House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2009 11.0 - - - - - NM